Quince Therapeutics director Marwan Sabbagh resigns effective Sept 30, 2022

Quince Therapeutics, Inc.

Dr. Marwan Sabbagh resigned from the Board effective September 30, 2022; no disagreement with company.
Board granted accelerated vesting of portion of March 14, 2022 stock option for service period.
Post-termination exercise period for vested stock option extended to 12 months after departure date.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Marwan Sabbagh

Member of the Board of Directors

QNCX · Quince Therapeutics, Inc.

Effective: 2022-09-30
Filed: September 30, 2022, 7:59 PM ET

On September 28, 2022, Marwan Sabbagh, M.D., a member of the Board of Directors (the “Board”) of Quince Therapeutics, Inc. (the “Company”), tendered his resignation from the Board, effective as of September 30, 2022 (the “Departure Date”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Marwan Sabbagh resigned as Member of the Board of Directors at Quince Therapeutics, Inc..

Action: resigned
Role: Member of the Board of Directors

Exact text from the filing

On September 28, 2022, Marwan Sabbagh, M.D., a member of the Board of Directors (the “Board”) of Quince Therapeutics, Inc. (the “Company”), tendered his resignation from the Board, effective as of September 30, 2022 (the “Departure Date”).

View on SEC.gov

Quince Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-255696

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.